Traduction de «treating these » (Néerlandais → Français) :

Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.

These strains are rare and emerge from MRSA strains in patients treated with a glycopeptide for longer periods of time.
Ces souches sont rares et proviennent de souches de MRSA chez les patients traités avec un glycopeptide pendant de plus longues périodes.

The progress made in treating depression has a positive influence on suicide prevention as a part of the care provided to these patients.
Les progrès dans le traitement de la dépression influencent positivement la prévention du suicide lors de la prise en charge.

Moreover, these patients rarely heed the referral to other specialists or the treatment administered for underlying problems after having been treated in the emergency service. In this project, the GPs are asked to actively follow the patients and to encourage them to receive post-hospital follow-up care (possibly provided by the hospital).
Dans ce projet, il est demandé au médecin généraliste de suivre le patient activement et de l’encourager à profiter du suivi post-hospitalier (éventuellement proposé par l’hôpital).

These programs have reduced the number of leprosy cases, with four million patients treated since 2000.
Il s’en est suivi une réduction des cas de lèpre, et quatre millions de malades ont été soignés depuis 2000.

Oncology Gleevec/Glivec (USD 2.9 billion, +12% lc), a targeted therapy for some forms of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST), has achieved sustained double-digit growth based on its leadership position in treating these cancers backed by new clinical data and regulatory approvals.
Oncologie Glivec/Gleevec (USD 2,9 milliards, +12% en m. l.), traitement ciblé contre certaines formes de leucémie myéloïde chronique (LMC) et de tumeurs stromales gastrointestinales (GIST), a enregistré une croissance soutenue à deux chiffres, grâce à sa position de leader dans le traitement de ces cancers, étayée par de nouveaux résultats cliniques et par des autorisations de mise sur le marché.

Gleevec/Glivec (USD 1.9 billion, +15% lc), a targeted therapy for certain forms of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST), has achieved sustained double-digit growth based on its leadership position in treating these cancers backed by new clinical data and regulatory approvals.
Glivec/Gleevec (USD 1,9 milliard, +15% en m. l.), traitement ciblé contre certaines formes de leucémie myéloïde chronique (LMC) et les tumeurs stromales gastrointestinales (GIST), a enregistré une croissance à deux chiffres, grâce à sa position de leader dans le traitement de ces maladies, étayée par de nouveaux résultats cliniques et par des autorisations de mise sur le marché.

Gleevec/Glivec (USD 3.9 billion, +12% lc), a targeted therapy for some forms of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST), achieved sustained double-digit growth based on its leadership position in treating these cancers backed by new clinical data and regulatory approvals.
Glivec/Gleevec (USD 3,9 milliards, +12% en m. l.), traitement ciblé contre certaines formes de leucémie myéloïde chronique (LMC) et de tumeurs stromales gastro-intestinales (GIST), a enregistré une croissance soutenue à deux chiffres, grâce à sa position de leader dans le traitement de ces cancers, étayée par de nouveaux résultats cliniques et par des autorisations de mise sur le marché.

These lawsuits are part of a number of actions pending against pharmaceutical companies that challenge the industry’s long-term practice of treating pharmaceutical sales representatives as salaried employees.
Ces plaintes font partie d’actions en justice intentées contre des sociétés pharmaceutiques qui contestent la pratique ancienne de l’industrie de considérer les délégués médicaux comme des employés salariés.